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Integrin-linked kinase (ILK) localizes to focal adhesions, and interacts with the cytoplasmic tail of b
subunits of integrins and couples them to the actin cytoskeleton. ILK may act as a kinase and transmit the
signals in a phosphatidylinositol 3-kinase-dependent manner, or can act as a scaffold protein to function
through cellematrix interactions, cell signaling, and cytoskeletal organization. Within this pivotal po-
sition, ILK mediates many important cellular processes, including survival, proliferation, differentiation,
adhesion, migration, contractility, etc. Besides, ILK plays some role in the activation of endothelial pro-
genitor cells and neovascularization, and may also enhance vascular endothelial growth factor expres-
sion. Increased ILK activity may promote epithelial-to-mesenchymal transition and induce a
transformed, tumorigenic phenotype. Higher expression of ILK was frequently noted in human malig-
nancies. ILK may also be important for mitotic-spindle assembly. Inhibition of ILK causes proliferative
defects, induces cell-cycle arrest and apoptosis, and is embryonically lethal. New concepts of gene or cell-
based therapy working on the up- or downregulation of ILK have emerged as a valid therapeutic
approach for cancer treatment, and also a new hope for vasculogenesis in the ischemic area. The current
review will discuss some knownmechanisms, and the role of ILK in the modulation of tumorigenesis and
reproduction, based on an extensive literature survey.
Copyright © 2014, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Integrin-linked kinase (ILK) is a key scaffold protein that local-
izes to focal adhesions, acts as a central component of a hetero-
trimer (the ILKePINCHeparvin complex). Since its discovery, ILK
has been demonstrated to have an essential role in connecting the
cytoplasmic tail of b subunits of integrins to the actin cytoskeleton,
and in regulating actin polymerization.1 Within this pivotal posi-
tion, ILK has been shown to interact with many intracellular pro-
teins through PINCH or parvin to mediate diverse arrays of
biological events,2 or to mediate cell responses induced by the
interaction of integrins with the extracellular matrix (ECM).2,3 ILK isof interest.
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for Gynecologic Endoscopy and Miniminvolved in the regulation of cell growth, survival, adhesion, inva-
sion, and migration. Increased ILK activity may promote epi-
thelialemesenchymal transition (EMT)4 and angiogenesis;
aberrantly overexpressed or activated ILK has also been found in
many types of human malignancies.5
The female reproductive system is strongly governed and
inﬂuenced by the cyclic ovarian hormones, and the endometrium
exhibits rapid cyclical shedding and regrowth throughout the fe-
male reproductive life. During the menstrual cycle, the endome-
trium undergoes cell proliferation and then decidualization, a
process of tissue remodeling for the preparation of embryo im-
plantation that includes molecular differentiation, morphological
transformation, ECM reorganization, as well as variations in
integrin moiety expression, which is called “integrin switching.”6
Three integrins, a1b1, a4b1, and avb3, coexpress at the window
of implantation.7,8 In addition, endometriosis and adenomyosis,
which are common pathologies of the female reproductive system
that induces signiﬁcant pelvic pain and subfertility, are caused byally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
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exact mechanism of pathogenesis remains elusive despite many
research efforts.9 Although endometriosis and adenomyosis are
generally thought to be benign diseases, malignancy can occur
unexpectedly in rare situations.10
As ILK acts in the center stage of cellematrix adhesion, and a
cyclic integrin switching takes place in endometrial cells
throughout the menstrual cycle, it is reasonable to assume that ILK
can play some important roles in endometrial functions of
decidualization and implantation, as well as in its unique pathology
of ectopic spread, or even in malignant transformation. In the
current review, a literature search was conducted to discuss some
known mechanisms by which ILK functions, the possible roles of
ILK in tumorigenesis and reproduction, and some prospects of ILK
as a therapeutic target.ILK is in the center stage of cellematrix adhesion and
signaling
Integrins are the major cell surface receptors that recognize and
bind ECM proteins, on which the communication between the cells
and ECM is based. Integrins are the prototypic transmembrane
receptors that induce the formation of focal adhesions. Upon
binding to its extracellular ligand, integrin would induce intracel-
lular signaling processes, involving molecules such as ILK or focal
adhesion kinase.11
ILK is a highly evolutionarily conserved intracellular protein,12
and is required for embryogenesis and tissue homeostasis, as
mice with ILK-conditional knockout are embryonic lethal shortly
after implantation due to defective epiblast polarization and
abnormal F-actin accumulation.13
Although there is a consensus that ILK is biologically important,
it remains controversial as to how ILK can confer its functions.
Recent structural, biochemical, and genetic analyses have revealed
that the protein kinase domain of ILK lacks some amino-acid resi-
dues thought to be essential for phosphotransferase activity;
instead, it contains multiple pseudoactive site features, includingFig. 1. Immunoﬂuorescent staining of the intracellular distribution of ILK and actin ﬁbers
without in vitro decidualization (treated with estradiol) and (DeF) with in vitro deciduali
stained with Texas-red labeling (in red), intracellular actin stress ﬁbers with phalloidin-FITC
expressed in a disperse fashion and the staining was fainter; however, in ESC with decidualiz
a dot or spot fashion). Bar ¼ 10 mm. DAPI ¼ 4',6-diamidino-2-phenylindole; ESC ¼ endomethe unusually short and rigid activation segment that lacks a
conserved phosphorylation site, altered magnesium coordination
topology, and a severely degraded catalytic loop. Although initially
named as a kinase, ILK is frequently questioned to be a
pseudokinase.2ILK may function as an adaptor/scaffold protein
Evidence has shown that ILK, a central piece of the
ILKePINCHeparvin complex in connecting integrins to the actin
cytoskeleton and other signaling proteins, functions primarily as an
adaptor/scaffold protein and works through proteineprotein in-
teractions.12 Dynamic interactions between cells and their envi-
ronments can also regulate their morphogenesis and functions.
Through the proteineprotein interaction mechanism, the ILK
scaffold transduces signals through its attachment to focal adhe-
sions and reorganization of the actin cytoskeleton and catalytic
proteins, and thereby regulates focal adhesion assembly, cytoskel-
eton organization, and signaling (Fig. 1). ILK is activated through
cellular interactions with the ECM and growth factors to mediate
many intracellular functional effects and cellular processes,
including growth, proliferation, survival, differentiation, migration,
invasion, and angiogenesis.14,15 Several studies have reported pro-
liferative defects upon ILK depletion.16 ILK also has central roles to
play in cardiac and smooth-muscle contractility, and ILK dysregu-
lation causes cardiomyopathies in humans.12 Increased ILK activity
may induce a transformed, tumorigenic phenotype, and may also
enhance vascular endothelial growth factor (VEGF) expression,
whereas inhibition of ILK induces apoptosis and cell-cycle arrest.5
ILK interacts directly with cytoplasmic domains of the b1 or b3
integrin subunits.15 Integrins (a1b1, a4b1, and avb3) coexpress in
the endometrium at the window of implantation,7,8 and the
expression of integrin a3b1 is also increased in cancer progres-
sion17; these integrins may be correlated to the ILK expression. ILK
regulates transmembrane signals bidirectionally,18,19 as they also
modulate extracellular ﬁbronectin ﬁbrillogenesis20 and ﬁbronectin
matrix assembly and deposition.21,22. Representative micrographs are ESCs obtained in one isolation and cultured (AeC)
zation (treated with estradiol plus medroxyprogesterone acetate) for 8 days. ILK was
(in green), and the nucleus with DAPI (in blue). ILK in ESC without decidualization was
ation, the expression of ILK was signiﬁcantly increased and more assembled (shown in
trial stromal cell; ILK ¼ integrin-linked kinase.
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As the debate went on, many recent in vitro studies showed that
ILK regulates phosphorylation of several key signaling in-
termediates, including phosphorylating protein kinase B (AKT1)
and glycogen synthase kinase-3b (GSK3B), and the phospho-
transferase activity of highly puriﬁed, full-length ILK. Therefore, ILK
is now accepted as a protein kinase, at least in vitro.12
It has previously been demonstrated that ILK achieves its
functions by controlling the phosphorylation of various down-
stream proteins, such as protein kinase B/Akt. ILK activates a range
of signaling pathways downstream of integrins through its serine/
threonine kinase activity. ILK transmits the signals in a phospha-
tidylinositol 3-kinase (PI3K)-dependent manner,23,24 during which
it regulates processes such as cell proliferation, survival, migration,
and invasion.25 Speciﬁcally, ILK phosphorylates and activates Akt at
Ser 473 that regulates the genes essential for survival.15,26 ILK also
directly phosphorylates GSK3b at Ser 9, inactivating it and leading
to activation of some transcription factors such as AP-1, b-catenin/
Tcf, and CREB. Induction of AP-1 also stimulates the expression of
matrix metalloproteinase (MMP)-9, which implicates ILK in the
process of invasion and metastasis; induction of b-catenin/Tcf and
CREB stimulates the overexpression of cyclin D1, which in turn
induces cell proliferation.15,27 Therefore, ILK acts as a multifunc-
tional serine/threonine kinase and regulates the functions of cell-
cycle progression, survival, migration, and invasion.
ILK functions contradictorily as both a proto-oncogene and a
tumor suppressor
Conventionally, ILK was noted with increased expression and
activity in many types of human malignancies and seemed to in-
crease with tumor grades, such as the gastric cancer, breast cancer,
and bladder cancer.28 In some of these cancer types, the expression
level could predict the poor outcome of the patient,12 and inhibition
of ILK has been shown to inhibit the growth, migration, invasion,
and angiogenesis of cancer cells.29 Hence, in some situations, ILK
can be considered as a proto-oncogene.
However, some recent studies revealed opposing functions of
ILK in the regulation of cell proliferation, differentiation, and
apoptosis. One example is that ILK acts as an oncogene in the highly
aggressive pediatric alveolar rhabdomyosarcoma, but contradicto-
rily as a tumor suppressor in the embryonal rhabdomyosarcoma.
The mechanism by which this occurred was found to involve the
kinase activity of ILK to interact with a JNK/c-Jun pathway, which
was altered by PAX3-FKHR, the aggressive pediatric alveolar
rhabdomyosarcoma-speciﬁc chromosomal fusion gene. The
expression of PAX3-FKHR would downregulate JNK1, suppress the
downstream signaling of JNK1/c-Jun, and cause ILK to behave as an
oncogene; however, restoration of JNK1 in aggressive pediatric
alveolar rhabdomyosarcoma re-established the tumor-suppressive
function of ILK.30 These results suggest a conserved role for ILK as a
tumor suppressor in certain mesenchymal lineage cells, and
expression of PAX3-FKHR in these cells rescued the dampened
growth induced by ILK overexpression, as in embryonal rhabdo-
myosarcoma cells.30
The ability to inhibit the ILK activity raised interest in ILK as a
target for anticancer therapy. Three cellular inhibitors of ILK
signaling, including phosphatase and tensin homolog deleted on
chromosome 10 (PTEN), ILKAP, and b-Parvin (ParvB), are known.
PTEN is a lipid phosphatase and a major antagonist of PI3K activity,
and dephosphorylation of PI(3,4,5)P3 by PTEN indirectly inhibits
ILK activity.31 ILKAP is a protein serine/threonine phosphatase of
the PP2C family, and selectively binds to and inhibits ILK, blocking
the phosphorylation of GSK3 S9.32 ParvB, another key componentof the PINCHeILKeparvin complex, was noted to be a prognostic
factor in some kinds of cancer.33 In a study of breast cancer, ParvB
inhibited ILK kinase activity and anchorage-independent cell
growth, and the loss of ParvB expression can upregulate ILK activity
in tumors.34
Some recent studies have also noted that ILK inhibitors, in
combination with conventional chemotherapeutic agents such as
gemcitabine or cisplatin, may be efﬁcacious in cancer patients35,36;
increased survival was observed in these patients, which was
signiﬁcantly more than the survival in those receiving either
treatment alone. Most recently, studies on a xenograft model of
EGFR-resistant human hepatoma-cell lines found that transfection
with kinase-inactive ILK increased the sensitivity of cells to the
EGFR inhibitors, which implied that the inhibition of ILK activity
might overcome the resistance to EGFR inhibitors.37
ILK is involved in EMT
ILK is identiﬁed as an important mediator of EMT, and the in-
crease of ILK activity is also suggested as a molecular marker for
EMT.4,14 EMT is a process through which cells lose epithelial
properties, such as cellecell adhesion and basoapical polarity, and
gain mesenchymal properties, such as increased ability to migrate
and invade through ECM proteins38; it describes a series of events
involving the alterations in morphology, cellular architecture,
adhesion, and migration capacity. It plays a role in three main
processes, namely, embryogenesis, tissue repair, and cancer inva-
sion/metastasis.39
Connecting with integrin, ILK downregulates E-cadherin
expression27 and is required for Transforming Growth Factor-b
(TGF-b)-induced EMT.40 In response to external triggers, ILK con-
verges those signals into the Rho family GTPases,41,42 and b1
integrins also activate RhoA and Rac1, which leads to the disruption
of cadherin-mediated adhesions.43 Together, these studies illus-
trate the role of ILK in cross-regulation between E-cadherin and
integrins.44
Pathological overexpression of ILK results in down regulation of
E-cadherin, and nuclear accumulation of b-catenin, and activation
of other mesenchymal genes through nuclear factor (NF)-kB.14,27,45
In a recent study of the overexpression of ILK on the human colo-
rectal cancer cell line SW480, the cells stably overexpressing ILK
underwent EMT, as indicated by mesenchymal morphology,
decreased expression of E-cadherin, and increased expression of
mesenchymal markers, as well as a dramatically promoted ability
of migration and invasion in vitro.46 Furthermore, applying the NF-
kB inhibitor or NF-kB p65 small interfering RNA (siRNA) signiﬁ-
cantly restored the reduced E-cadherin level in these ILK-
overexpressing cells, suggesting that ILK-mediated EMT is depen-
dent on NF-kB activation.46
In a similar manner, inhibition of ILK signaling may reverse the
EMT process and hinder cancer growth. Human ribonuclease in-
hibitor (RI), a cytoplasmic acidic protein that inhibits RNase A and
angiogenin activities, was shown to inhibit growth and metastasis
in some cancer cells.47 In human clinical specimens, bladder cancer
with a high metastasis capability shows higher expression of
vimentin, Snail, Slug, and Twist, and lower expression of E-cadherin
and RI. However, overexpression of RI would decrease the ILK
expression, reduce phosphorylation of the ILK downstream
signaling targets p-Akt and p-GSK3b, and reverse the process of
EMT. Speciﬁcally, overexpression of RI induces upregulation of E-
cadherin and inhibits the expression of MMP-2, MMP-9, and other
mesenchymal markers, such as N-cadherin, Snail, Slug, vimentin,
and Twist in vitro. Overexpression of RI also inhibits cell prolifera-
tion, migration, and invasion; alters cell morphology and adhesion;
and leads to the rearrangement of the cytoskeleton in vitro.
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through inhibition of ILK signaling and reversal of the EMT
process.47
In a study of tongue cancer, tumors with a high metastasis
capability showed higher expression of ILK and mesenchymal
markers, such as vimentin, Snail, Slug, and Twist, as well as lower
expression of E-cadherin in clinical specimens. However, ILK siRNA
inhibited EMT, cell proliferation, migration, and invasion, as well as
changed cell morphology.48 The study also demonstrated that ILK
siRNA inhibited phosphorylation of downstream signaling targets
Akt and GSK3b, as well as reduced the expression of MMP-2 and
MMP-9, leading to the suppression of tumorigenesis andmetastasis
in vivo.48
ILK plays roles in vascular biology
New vessel formation is a dynamic process of interactions be-
tween endothelial cells (ECs) and endothelial progenitor cells (EPCs)
and between each of them and the ECM.49 As ILK plays a pivotal role
in ECM-mediated signaling, studies revealed that ILK is a key
molecule in the vascular biology, particularly the function, struc-
ture, and survival of ECs, and the process of neovascularization.50
In a study using the model of human umbilical vein ECs,
endogenous ILK expression was decreased in various stress condi-
tions, and retarded capillary tube formation was noted after a brief
anchorage deprivation. However, adenoviral ILK gene transfer in
ECs and EPCs reversed the decrease in cell survival signals, and
signiﬁcantly accelerated the functional recovery after reattach-
ment. In the nude mice hindlimb ischemia model, the ILK-
overexpressing EPCs signiﬁcantly improved blood ﬂow recovery
and prevented limb loss.51 As the ILK/Akt/GSK3b axis is activated in
ECs and EPCs, it is speculated that ILK functions as an effecter of
PI3K signaling, which regulates protein kinase B/Akt activity posi-
tively and GSK3 activity negatively.52
Possible role of ILK in mitosis
Recently a global analysis of the ILK “interactome” found that
several centrosomal and mitotic-spindle proteins are binding
partners of ILK, which implied that ILK might be important for
mitotic-spindle assembly and have some roles in mitosis.15,53
Further study demonstrated that ILK could be found in focal ad-
hesions and centrosomes simultaneously in interphase cells, and
ILK inhibition induced dramatic defects in mitotic-spindle organi-
zation, which indicates that ILK may be important for mitotic-
spindle assembly.54 Removal of ILK from hepatocytes in vivo has
also been shown to cause mitotic defects.55 It is likely that due to its
role in mitosis, ILK can have some prospects of application in cell-
based therapy against cancer.15
ILK's role in reproduction
ILK protein is highly detectable in placental tissue samples
throughout gestation and highly expressed in human trophoblast
during the 1st trimester of pregnancy. In a recent study, the
dominant negative ILK trophoblast cell line showed dramatically
reduced migration into wounds compared to cells expressing wild-
type ILK, indicating that the ILK may promote trophoblastic cell
migration during this period of development.25
In patients of pre-eclampsia, a speciﬁc hypertensive and vascular
complication inpregnancy, both theexpressionof ILKand thenumber
of EPCs (precursors of ECs) were diminished. While EPCs were
transfected with the ILK gene, growth and angiogenic activities of
EPCs were enhanced.56 Another study showed that transfectionwith
ILK also enhanced the proliferative, migratory, and angiogeniccapabilities of EPCs, and promoted VEGF production.57 These results
imply that the ILK gene transfection is effective in augmenting the
angiogenic activity of EPCs, hence a therapeutic potential for cell-
based gene therapy in patients with pre-eclampsia.57
Conclusion and perspectives
ILK is now considered as a complex, multifunctional protein that
dynamically regulates signals derived from integrinematrix in-
teractions or serine/threonine kinase activity through intermolec-
ular interactions and kinase activity. ILK regulates cellematrix
interactions, cytoskeletal organization, and cell signaling with
indispensable roles in embryonic development, and may also be
important for mitotic-spindle assembly. Therefore, ILK has many
important contributions to various cellular processes, including
survival, proliferation, differentiation, adhesion, migration, and
contractility. Inhibition of ILK causes proliferative defects, induces
cell-cycle arrest and apoptosis, and is embryonically lethal.
Increased ILK activity may promote EMT; induce a transformed,
tumorigenic phenotype; and enhance VEGF expression.5 In addi-
tion, as ILK plays some role in the activation of EPCs and neo-
vascularization, strategies targeting ILK overexpression may be
highly effective in cell-based therapeutic vasculogenesis in
ischemic area.51
Greater expression of ILK was frequently noted in human ma-
lignancies, which has emerged as a valid therapeutic target in
cancer. Speciﬁc inhibitors of ILK kinase activity have exhibited
growth arrest and apoptosis in cells in vitro and in vivo, providing
support for ILK as a therapeutic target in human cancer.15 Of crucial
importance, ILK inhibitors were tolerated well and exhibited no
apparent toxicity in these studies.
It will be of great interest to delineate the exact functions and
targets of ILK in centrosomes during the mitotic process, as mitotic
defects are hallmarks of malignant cells, and due to its role in
mitosis ILK can have some prospects in cell-based therapy against
cancer.15 However, it is still uncertain whether the centrosomal ILK
has similar signaling targets (such as Akt, GSK3, and catenin) to
conventional ILK known in focal adhesions, and the diversities of
ILK function seem to be cell and/or tissue speciﬁc and dependent on
contextual cues. Future breakthroughs can arise from an in-depth
analysis of the many direct and indirect interactions associated
with ILK in this ﬁeld.
After all, the roles of ILK in reproductive sciences were under-
explored. Although the function of ILK on trophoblastic cells and
EPCs in pre-eclampsia have been studied in some publications, the
possible roles of ILK in other interesting tissues such as the decidual
cells and the ectopic endometrial cells of endometriosis and ade-
nomyosis havemerit for further investigation. The current standard
of diagnosis and treatment of endometriosis is through the lapa-
roscopy,58,59 in which a tissue biopsy is usually available for further
research. Many investigators believe that the eutopic endometrium
and embedded immune-related cells may exhibit altered charac-
teristics and interactions,60 which may also affect the implantation
process of the embryo. Besides, one potential cause of reproductive
failures such as infertility and recurrent miscarriage may arise from
the endometrial defect of cell communication or adhesion func-
tions.61 The exact mechanism of pathogenesis is still elusive, and
the possible role of ILK in cell adhesion, EMT, or abnormal function
of mitosis and proliferation would be interesting topics for further
investigation.
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